Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios

Cerebrospinal fluid (CSF) biomarker ratios were never evaluated in late‐onset (>65 years) behavioral variant of frontotemporal lobar degeneration (bvFTLD) versus Alzheimer's disease (AD).

• Publication year

  2015

• Venue

  Alzheimer's & Dementia

• Publication date

  2015-06-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.dadm.2015.06.004PMID 27239517PMCID 4878372
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?

  2015cited by this paper
• A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles

  2014cited by this paper
• Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

  2013cited by this paper
• A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers

  2013cited by this paper
• Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

  2012cited by this paper
• CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

  2012influential reference
• Frontotemporal dementia in elderly individuals.

  2012cited by this paper
• Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates

  2012cited by this paper
• Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis.

  2012cited by this paper
• Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

  2011cited by this paper
• Pathological correlates of frontotemporal lobar degeneration in the elderly

  2011cited by this paper
• Visual assessment of posterior atrophy development of a MRI rating scale

  2011cited by this paper
• Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias

  2010influential reference
• Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

  2010cited by this paper
• # The Author(s) 2011. This article is published with open access at Springerlink.com

  2010cited by this paper
• CSF biomarkers in frontotemporal lobar degeneration with known pathology

  2008cited by this paper
• Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

  2003cited by this paper
• Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

  1999influential reference
• Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

  1992cited by this paper
• Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter. A comparative study between stroke patients and normal volunteers.

  1992cited by this paper
• MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging.

  1987cited by this paper
• The measurement of observer agreement for categorical data.

  1977cited by this paper

• Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer’s Disease or Other Neurological Diseases

  2023cites this paper
• Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia

  2023cites this paper
• Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges.

  2022cites this paper
• Synergistic Association between Plasma Aβ1–42 and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia

  2021cites this paper
• Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset

  2021cites this paper
• Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

  2020cites this paper
• Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

  2020cites this paper
• Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia

  2020cites this paper
• Pathophysiological and structural underpinnings of frontotemporal lobar degeneration: a multimodal biomarker study

  2019cites this paper
• Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy.

  2019cites this paper
• Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale

  2018cites this paper
• Interprétation des biomarqueurs du liquide céphalorachidien dans la maladie d’Alzheimer et les dégénérescences lobaires fronto-temporales

  2017cites this paper